Can a Type 1 Diabetic Donate Organs?

People with type 1 diabetes can donate organs after death, and their organs routinely save lives. Living kidney donation is a different story: every major guideline treats type 1 diabetes as a disqualifying condition for that specific scenario. But the question of deceased donation is far more nuanced than most people realize, and the research on how diabetic organs perform once transplanted contains some genuinely surprising findings.

Why Living Kidney Donation Is Off the Table

If you have type 1 diabetes and want to donate a kidney to a family member or friend while you’re alive, the answer from transplant programs worldwide is no. A review of international guidelines found that type 1 diabetes is treated as an absolute contraindication for living kidney donation across all major frameworks, including those from the British Transplantation Society and KDIGO (Kidney Disease: Improving Global Outcomes).¹ The reasoning is straightforward: donating a kidney leaves you with one, and type 1 diabetes already puts that remaining kidney at elevated risk of damage over time. No transplant team will accept that trade-off for the donor.

This stands in contrast to type 2 diabetes, where some guidelines leave the door open depending on individual circumstances. But for type 1, the consensus is uniform. That unanimity should actually be reassuring in a way: it means nobody is going to pressure you into a decision that puts your health at unacceptable risk.

Deceased Donation Is a Different Calculation

Once the question shifts from living donation to deceased donation, the math changes completely. The donor’s long-term kidney health is no longer a concern because the donor has died. The only question becomes whether the organ can function well enough in the recipient to justify transplantation. And the evidence says that in many cases, it can.

A large national analysis of U.S. transplant data found that kidneys from deceased diabetic donors did carry somewhat higher rates of graft failure and recipient death compared to kidneys from non-diabetic donors. The hazard ratio for graft failure was about 1.2, meaning roughly a 20% relative increase in risk.² That sounds concerning in isolation. But context matters enormously here, because the alternative for many patients on the transplant waitlist is not a perfect kidney from a young, healthy donor. The alternative is staying on dialysis.

An analysis of the UNOS registry over a ten-year period found that kidneys from diabetic standard-criteria donors actually performed significantly better than kidneys from non-diabetic expanded-criteria donors, which are organs from older or medically complex donors that transplant centers already accept regularly.³ Recipients of diabetic donor kidneys in that study were also less likely to experience delayed graft function than recipients of expanded-criteria kidneys. So discarding diabetic donor kidneys entirely would mean throwing away organs that outperform alternatives many patients already receive.

Who Receives the Kidney Matters as Much as Who Donates It

One of the more striking findings in this field is that the recipient’s own diabetes status dramatically shapes outcomes. A study examining donor-recipient diabetes combinations found that non-diabetic recipients who received a kidney from a diabetic donor had no difference in graft survival compared to non-diabetic recipients who got a kidney from a non-diabetic donor.⁴ Patient survival was also equivalent. The trouble emerged mainly when both the donor and the recipient had diabetes: in that pairing, graft survival dropped significantly.

The national outcomes study found a similar interaction. When researchers compared recipients of kidneys from the same diabetic donor, with one recipient having diabetes and the other not, the diabetic recipient had a markedly higher risk of graft failure and death.² This “double diabetes” effect suggests the problem is not simply that diabetic donor kidneys are damaged goods, but that the metabolic environment of a diabetic recipient compounds any existing vulnerabilities. For a non-diabetic person waiting on the list, a kidney from a type 1 diabetic donor can be a perfectly reasonable option.

Diabetic Kidney Damage Can Actually Reverse

This is where the science gets genuinely fascinating. Diabetic nephropathy, the kidney damage caused by years of high blood sugar, has long been considered a one-way street in living patients. But transplanting a diabetic kidney into a non-diabetic body removes the metabolic environment that caused the damage in the first place. And the kidney sometimes heals.

The earliest and most dramatic demonstration of this came from a case in which two kidneys from a cadaveric donor with a 17-year history of type 1 diabetes were transplanted into non-diabetic recipients. The donor’s kidneys showed established diabetic nephropathy at the time of transplant, including diffuse scarring and thickened membranes. Seven months later, biopsies showed almost complete resolution of the nephropathy, and both recipients remained free of protein in their urine.⁵

More recent work has confirmed this pattern, though the degree of recovery varies. A study tracking protocol biopsies at one hour, one month, and one year after transplantation found that early diabetic changes visible at the one-hour and one-month biopsies were reversed and improved by the one-year mark.⁶ Another study found that in about three-quarters of cases the diabetic changes held stable, with roughly 7% showing regression and about 18% showing some progression.⁷ Stability rather than worsening is the norm, and in a meaningful minority the damage partially reverses. This finding doesn’t mean every diabetic kidney is a good transplant candidate, but it does challenge the assumption that diabetes-related structural changes are irreversible once they appear.

What Transplant Teams Look for in Diabetic Donor Organs

Not all diabetic donor kidneys are created equal, and transplant teams use several tools to decide which ones are suitable. One is the biopsy itself. A pathology study of kidneys from diabetic deceased donors found that vascular disease, including arterial stiffening and small-vessel damage, was the most common abnormality, appearing in the vast majority of samples. Glomerular abnormalities showed up in about a third, including the characteristic scarring patterns of diabetic kidney disease.⁸ Kidneys with more extensive damage performed worse, which is intuitive. The duration of the donor’s diabetes and the severity of structural changes at the time of procurement both predicted shorter graft survival.

Another screening tool is hemoglobin A1c, a blood marker that reflects average blood sugar levels over the preceding two to three months. For kidney transplantation from diabetic donors, an A1c of 6.5% or higher was independently associated with worse graft survival. Five-year graft survival was roughly 59% in the higher A1c group compared to about 68% in donors whose A1c was below that threshold.⁹ For liver allografts from non-diabetic donors, elevated A1c was also linked to reduced graft survival, suggesting the test has value even in donors not formally diagnosed with diabetes.¹⁰

The concept of “expanded criteria” donors formally acknowledges that organs from older donors or those with medical histories including diabetes or hypertension carry somewhat higher risk but still offer meaningful benefit. The term was deliberately chosen over the older label “marginal” because, as transplant experts pointed out, calling an organ marginal stigmatizes both the patients who receive these organs and the programs willing to use them.¹¹

Livers From Type 1 Diabetic Donors

Kidneys get most of the research attention because diabetic nephropathy is so well characterized, but livers from diabetic donors are transplanted too, and the outcomes are reasonably good. A nationwide Dutch retrospective study compared early and medium-term outcomes for liver transplants from type 1 versus type 2 diabetic donors. Three-year graft survival was about 79% for recipients of type 1 diabetic livers and 78% for type 2 diabetic livers, with patient survival similarly close between the groups.¹² The researchers did observe that the incidence of a bile-duct complication was nearly twice as high in livers from type 1 diabetic donors compared to type 2, though the difference was not statistically significant given the small numbers. Overall, the type of donor diabetes did not meaningfully separate outcomes.

One broader takeaway from the liver data is that donor diabetes generally does carry some risk compared to non-diabetic donors, but neither type 1 nor type 2 stands out as clearly worse than the other. Transplant teams weigh these risks against the recipient’s urgency and the availability of alternative organs.

Corneal and Tissue Donation

Organ donation gets the headlines, but tissue donation, including corneas, skin, bone, and heart valves, is far more common and helps many more people per donor. For type 1 diabetics considering whether to register as donors, the cornea question is especially relevant because diabetes is known to affect the eye in multiple ways.

The good news is clear. A large study published in JAMA Ophthalmology found that the presence of diabetes, even severe diabetes, was not associated with poor suitability for corneal transplantation based on endothelial tissue examination. Diabetic donors did not exhibit significantly lower endothelial cell counts after adjusting for age and other factors.¹³ A separate study did find that insulin-dependent diabetic donors with medical complications from their diabetes had modestly lower endothelial cell density compared to non-diabetic donors, but even in that group the likelihood of being deemed suitable for endothelial transplantation did not differ from the other groups.¹⁴

In practical terms, this means that registering as an organ and tissue donor when you have type 1 diabetes is still likely to benefit someone. Even if certain solid organs turn out to be unsuitable at the time of death, corneal and other tissue donations may well proceed.

The Pancreas Is the Exception

There is one organ where type 1 diabetes creates an obvious problem, and it is the pancreas itself. Pancreas transplants and islet-cell transplants are performed specifically to treat type 1 diabetes, so the organ needs to have functioning insulin-producing cells. A pancreas from a donor with type 1 diabetes has, by definition, lost those cells to autoimmune destruction, making it unsuitable for transplantation as a therapeutic organ.

That does not mean these pancreata go to waste. The Network for Pancreatic Organ Donors with Diabetes (nPOD) was established specifically to recover and characterize pancreata from cadaveric donors with type 1 diabetes at various stages. These specimens are made available to researchers studying the natural history and underlying mechanisms of the disease.¹⁵ The program has been valuable for understanding how the autoimmune attack on beta cells unfolds, because pancreatic tissue from people with type 1 diabetes is extremely difficult to study during life. In a sense, donating your pancreas to research when you have type 1 diabetes is one of the most direct ways to contribute to eventually curing the disease that affected you.

Donor Management Before Procurement

When someone with type 1 diabetes becomes a potential organ donor after brain death, the medical team managing the donor’s body faces some specific challenges. Brain death triggers a cascade of hormonal and metabolic disruptions, and managing blood sugar becomes an immediate concern. One common approach is “hormone resuscitation therapy,” which can include insulin administration. But research on this practice has raised questions: a study examining whether insulin administration during donor management improved organ yield found that insulin was almost never beneficial and was at times associated with a reduced yield of transplantable organs, particularly the pancreas and intestine.¹⁶ This is relevant because it means the management of a type 1 diabetic donor’s body in the hours before organ procurement requires careful judgment, not a reflexive protocol.

For pancreas allocation specifically from non-diabetic donors, the A1c level at the time of donation is checked as part of organ assessment. A single-center analysis found that among otherwise transplantable pancreata, donor A1c levels between 3.5% and 6.2% were not associated with different short-term outcomes.¹⁷ This kind of fine-grained metabolic screening helps transplant teams distinguish between organs that carry acceptable risk and those that do not.

What This Means If You Have Type 1 Diabetes

The bottom-line practical takeaway is that you should absolutely register as an organ and tissue donor. The decision about which specific organs are suitable for transplantation is made at the time of death by transplant professionals who evaluate each organ individually. Having type 1 diabetes does not disqualify you from deceased donation. Your kidneys, liver, heart, lungs, corneas, and other tissues may all be candidates depending on their condition. The one organ that will not be used therapeutically is your pancreas, but it can still contribute to research.

You will not be able to donate a kidney while alive. That restriction is clear and consistent across guidelines. But the vast majority of organ donation occurs after death, and in that context, a type 1 diabetes diagnosis is a factor the transplant team considers, not a reason to exclude you. Given the persistent shortage of donor organs worldwide, with waitlists far exceeding supply in every country, the transplant community has moved firmly toward using well-screened diabetic donor organs rather than discarding them. The evidence supports that approach, particularly when the recipients are carefully matched and the organs are properly evaluated beforehand.